Interprofessional Considerations in the Management of Pulmonary Arterial Hypertension

Activity Description

Most healthcare providers are not likely to encounter a meaningful amount of PAH patients potentially leading to a gap in initial diagnosis. This interprofessional activity will focus on the diagnosis gap, individualized treatment strategies, and patient-centered care practices for managing PAH treatments. The activity will begin with foundational PAH pathophysiology, then include a deep dive into PAH therapies and the most recent data surrounding their uses. Faculty will also discuss important patient-centric adverse effect management and quality of life discussions.

Target Audience

The target audience for this activity includes pharmacists, nurses, physicians and physician assistants.

Learning Objectives

At the completion of this activity, the participant will be able to:

  • Examine the underlying pathogenic pathways, progression, and presentation of pulmonary arterial hypertension (PAH)
  • Compare and contrast current and emerging PAH treatments by mode of delivery, mechanism of action, adverse effects, and monitoring parameters
  • Discuss strategies to manage iatrogenic and progression-related scenarios to improve quality of life for PAH patients

Faculty

James C. Coons, PharmD, FCCP, BCCP
Associate Professor
University of Pittsburgh School of Pharmacy
Clinical Pharmacist, Cardiology
University of Pittsburgh Medical Center-Presbyterian Hospital
PGY2 Cardiology Residency Program Director
Pittsburgh, Pennsylvania

Martha Kingman, DNP, FNP-C
Nurse Practitioner
Pulmonary Hypertension Program
University of Texas Southwestern Medical Center at Dallas
Dallas, Texas

Vallerie McLaughlin, MD
Kim A. Eagle MD Endowed Professor of Cardiovascular Medicine
Director of the Pulmonary Hypertension Program
University of Michigan
Ann Arbor, Michigan

CME/CE Accreditation

Release Date: March 4, 2021
Expiration Date: March 4, 2022

ACPE Credit Designation (Pharmacist CE)

ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-21-017-H01-P has been assigned to this home study knowledge-based activity. This activity is approved for 1.25 contact hour (0.125 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Completion of an evaluation and post-test with a score of 70% or higher is required to receive CE credit. Proof of completion will be posted in NABP CPE Monitor profiles. No partial credit will be given.
 


Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by ProCE, LLC and Clinical Care Options, LLC (CCO). Clinical Care Options, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
 

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 

Nursing Continuing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.25 contact hours.
 

AAPA Credit Designation
Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.25 AAPA Category 1 CME credits. Approval is valid until 3/4/2022. PAs should only claim credit commensurate with the extent of their participation.
 

Disclosure

It is the policy of ProCE, LLC to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation.

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty and planners reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Dr. Coons has conducted contracted research for Pfizer and United Therapeutics; received consulting fees from Alnylam and Bristol Myers Squibb.
Dr. Kingman has received consulting fees from Actelion/J&J, Bayer, and United Therapeutics.
Dr. McLaughlin has conducted contracted research for and received consulting fees from Acceleron, Actelion, and United Therapeutics; received consulting fees from Altavant, Caremark, CiVi Biopharma, Gossamer Bio, and Liquidia ; conducted contracted research for Reata and Sonavie.
CCO and ProCE Staff have no relevant conflicts of interest to report.
Mr. Thibodeau does not have any relevant conflicts of interest to report.

Potential conflicts of interest were resolved with a peer review process provided by Daniel Thibodeau, MHP, PA-C, DFAAPA.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Funding

This activity is supported by an educational grant from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson.

    

The material presented in this CE activity does not reflect the views of ProCE, LLC or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.